ICER publishes protocol for annual assessment of drug coverage policies that present barriers to fair access

12 April 2023 - ICER will evaluate whether multiple formularies offered by the five largest US commercial payers, state health exchange ...

Read more →

New generation of weight loss medications offer promise — but at a price

11 October 2022 - Excitement is building about a new generation of drugs that tout the ability to help adults ...

Read more →

Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement

4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...

Read more →

ICER publishes white paper evaluating reforms to orphan drug development, pricing and coverage

7 April 2022 - The white paper presents an analysis of the potential risks and benefits of reforms seeking to ...

Read more →

ICER to test principle of fair access to fairly priced pharmaceuticals

2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease ...

Read more →

New analysis shows using ICER’s value assessments would limit access to life-saving medicines in Medicare Part B

31 May 2018 - 62 to 93% of Medicare Part B beneficiaries with serious, complex conditions could lose access to their ...

Read more →

Americans thought they would get a PHARMAC from Trump

15 May 2018 - If New Zealand was showing any interest in a bilateral trade agreement with the United States, ...

Read more →

When cholesterol drugs cost $14,000, an insurance tug-of-war

19 June 2017 - Patients struggle to obtain PCSK9 inhibitors, a powerful class of drugs that lower bad cholesterol in difficult ...

Read more →

Another voice: Patients have a right to the treatments ordered by doctors

22 May 2017 - For too long, insurance-backed groups have been given enormous power to overrule doctors’ orders and make ...

Read more →